SOLVO Biotechnology | A Charles River Compan

solvo.com

With 17 years of experience and 500 customers in 40 countries, SOLVO Biotechnology is the leading provider of transporter services and products. Leveraging our expertise in efflux and uptake transporters, SOLVO generates quality reports for submission to FDA/EMA. From small molecules to protein therapeutics, SOLVO can test all your transporter needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

BAYER AND BICYCLE THERAPEUTICS ENTER STRATEGIC COLLABORATION FOR DEVELOPMENT OF NOVEL TARGETED RADIONUCLIDE THERAPIES IN ONCOLOGY

Businesswire | May 11, 2023

news image

Bayer and Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured a...

Read More

Diagnostics

PHENOMIX SCIENCES ANNOUNCES FIRST OBESITY BIOBANKING REGISTRY AND OUTCOMES STUDY FOR PRECISION NUTRITION AND OBESITY

Phenomix Sciences | May 27, 2022

news image

Phenomix Sciences (Phenomix), a precision biotechnology company bringing data intelligence to the treatment of obesity, announces today the launch of its biobanking registry and outcome study. The registry will study variability in obesity by looking at patients' DNA, metabolomics, hormones, patient behavior, assessments, and treatment outcomes. The data collected will supplement the 20 billion unique data points that make up the Phenomix Sciences Obesity Platform. Mayo Clinic is the first t...

Read More

Medical

VERNAL BIOSCIENCES ANNOUNCES STRATEGIC LEADERSHIP APPOINTMENTS TO DRIVE GROWTH IN MRNA AND LNP FORMULATION

Vernal Biosciences | January 03, 2024

news image

<p> Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of Sven Lee, Chief Commercial Officer, and Richard P. Hamel, Chief Financial Officer to its leadership team. Both distinguished leaders will strengthen Vernal&rsquo;s position as a premier mRNA and LNP Contract Development and Manufacturing Organization (CDMO) while using their deep experience to deliver Vernal&rsquo;s i...

Read More

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

news image

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More
news image

Medical, Industry Outlook

BAYER AND BICYCLE THERAPEUTICS ENTER STRATEGIC COLLABORATION FOR DEVELOPMENT OF NOVEL TARGETED RADIONUCLIDE THERAPIES IN ONCOLOGY

Businesswire | May 11, 2023

Bayer and Bicycle Therapeutics plc a biotechnology company pioneering a new and differentiated class of therapeutics by utilizing proprietary bicyclic peptides technology (Bicycle®), announced that they have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured a...

Read More
news image

Diagnostics

PHENOMIX SCIENCES ANNOUNCES FIRST OBESITY BIOBANKING REGISTRY AND OUTCOMES STUDY FOR PRECISION NUTRITION AND OBESITY

Phenomix Sciences | May 27, 2022

Phenomix Sciences (Phenomix), a precision biotechnology company bringing data intelligence to the treatment of obesity, announces today the launch of its biobanking registry and outcome study. The registry will study variability in obesity by looking at patients' DNA, metabolomics, hormones, patient behavior, assessments, and treatment outcomes. The data collected will supplement the 20 billion unique data points that make up the Phenomix Sciences Obesity Platform. Mayo Clinic is the first t...

Read More
news image

Medical

VERNAL BIOSCIENCES ANNOUNCES STRATEGIC LEADERSHIP APPOINTMENTS TO DRIVE GROWTH IN MRNA AND LNP FORMULATION

Vernal Biosciences | January 03, 2024

<p> Vernal Biosciences, a leading manufacturing and services company specializing in mRNA and lipid nanoparticle (LNP) formulation, proudly announces the additions of Sven Lee, Chief Commercial Officer, and Richard P. Hamel, Chief Financial Officer to its leadership team. Both distinguished leaders will strengthen Vernal&rsquo;s position as a premier mRNA and LNP Contract Development and Manufacturing Organization (CDMO) while using their deep experience to deliver Vernal&rsquo;s i...

Read More
news image

Cell and Gene Therapy

CELLISTIC AND CELYAD ONCOLOGY ANNOUNCE GMP CELL THERAPY MANUFACTURING OPERATIONS TRANSACTION

Cellistic and Ncardia | September 20, 2022

Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced today a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice grade cell therapy manufacturing capability, including the existing facility and all related personnel. Under the terms of an asset ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us